Bortezomib for acute antibody-mediated rejection in liver transplantation

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2526-2531

  Paterno, F ^a   Shiller, M ^a   Tillery, G ^a   O'Leary, J G ^a   Susskind, B ^a   Trotter, J ^a   Klintmalm, G B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibody mediated rejection; bortezomib; crossmatch; donor specific antibodies; HLA compatibility; liver transplantation

Indexed keywords

BORTEZOMIB; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD COMPATIBILITY; CASE REPORT; DISEASE SEVERITY; FEMALE; GRAFT REJECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PLASMA CELL; PRIORITY JOURNAL; T CELL DEPLETION;

ADULT; ANTIBODIES; BORONIC ACIDS; FEMALE; GRAFT REJECTION; HUMANS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 84865593513     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04126.x     Document Type: Article

References (20)

1. Takemoto SK, Zeevi A, Feng S, et al,. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041. (Pubitemid 38868592)
2. Chan KM, Lee CS, Wu TJ, Lee CF, Chen TC, Lee WC,. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation 2011; 91: e29-e30.
3. Kamar N, Lavayssière L, Muscari F, et al,. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426-3430.
4. Watson R, Kozlowski T, Nickeleit V, et al,. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
5. Kozlowski T, Rubinas T, Nickeleit V, et al,. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
6. Musat AI, Agni RM, Wai PY, et al,. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
7. O'Leary JG, Kaneku H, Susskind BM, et al,. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
8. Morioka D, Togo S, Kumamoto T, et al,. Six consecutive cases of successful adult ABO-incompatible living donor liver transplantation: A proposal for grading the severity of antibody-mediated rejection. Transplantation 2008; 85: 171-178. (Pubitemid 351156846)
9. Raut V, Uemoto S,. Management of ABO-incompatible living-donor liver transplantation: past and present trends. Surg Today 2011; 41: 317-322.
10. Colvin RB,. C4d in liver allografts: A sign of antibody-mediated rejection? Am J Transplant 2006; 6: 447-448. (Pubitemid 43382130)
11. Rostron A, Carter V, Mutunga M, et al,. A case of acute humoral rejection in liver transplantation: Successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005; 18: 1298-1301. (Pubitemid 41726751)
12. Ratner LE, Phelan D, Brunt EM, Mohanakumar T, Hanto DW,. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993; 55: 814-819. (Pubitemid 23122054)
13. Wilson CH, Agarwal K, Carter V, et al,. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006; 82: 988-989. (Pubitemid 44564051)
14. Flechner SM, Fatica R, Askar M, et al,. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492.
15. Walsh RC, Everly JJ, Brailey P, et al,. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
16. Everly MJ, Everly JJ, Susskind B, et al,. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
17. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658-663.
18. Sakashita H, Haga H, Ashihara E, et al,. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: 676-684. (Pubitemid 46788874)
19. Lunz J, Ruppert KM, Cajaiba MM, et al,. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: Can C4d stains help in monitoring? Am J Transplant 2012; 12: 171-182.
20. Ali S, Ormsby A, Shah V, et al,. Significance of complement split product C4d in ABO-compatible liver allograft: Diagnosing utility in acute antibody mediated rejection. Transpl Immunol 2012; 26: 62-69.